Phase 4 Haemophilia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with congenital (inherited from birth) haemophilia A, with a very low level of the clotting protein Factor VIII (less than 6 IU/ml)
• People who are older than 1 year at the time of joining (children aged 1–16 years may be considered after an interim review of trial data, as described in the study protocol)
• People who have been taking emicizumab at a standard dose (6 mg/kg every 4 weeks, with some variation in timing) for at least 12 months before joining
• People whose bleeding has been well controlled — meaning no spontaneous joint or muscle bleeds in the past 6 months, and no more than two treated bleeds caused by injury in the past 6 months
• People who are willing and able to give written consent to participate, or whose parent or legal guardian is able to give that consent on their behalf
• People who are willing to share information about any bleeding episodes during the trial
• People who are willing to follow the medication schedule required by the trial

Who may not be able to join:

• People whose haemophilia A was acquired (developed during their lifetime rather than being present from birth)

Important: Always verify eligibility with the trial site directly before applying.